Grant of Director Share Options

About this update from Thalia Therapeutics Plc

23 July 2026   Thalia Therapeutics plc   ("Thalia" or the "Company")   Grant of Director Share Options   Thalia Therapeutics plc (AIM: THAT), a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces that it has granted options over a total of   200,000,000 ordinary shares   in the Company (the "Options") to certain directors under the Company's share option plan.   Following the Annual General Meeting and completion of the acquisition of Sanmirna Therapeutics Inc (the "Acquisition") as announced on 17 July 2026, the Board believes that the grant of Options provides an appropriate long-term incentive, aligning the interests of the Directors with those of shareholders and supporting the delivery of the Company's strategic and commercial objectives.   Key terms of the Options ·      Total of   200,000,000 Options   granted to five directors ·      Exercise price of   0.6 pence per ordinary share , being equal to the recent subscription price ·      Ten-year term from the date of grant ·      50% (100,000,000) of the Options vest subject to continued appointment, in three equal tranches on the first, second and third anniversaries of the grant date, being 20 July 2026 ·      The remaining 50% (100,000,000) vest only upon achievement of share price performance targets: o  25% of the total award vests if the Company's share price reaches   1.2 pence per share , representing a doubling of the recent subscription price; and o  25% of the total award vests if the Company's share price reaches   1.8 pence per share , representing a tripling of the recent subscription price   The Options represent approximately   11.25%   of the Company's current issued share capital (excluding the new option shares). On a fully diluted basis, including outstanding convertible loan notes, warrants and these Options, the awards represent approximately   7.5%   of the Company's enlarged fully diluted share capital, prior to the issue of any future milestone payments under the share purchase agreement pertaining to the Acquisition.   Director option grants   Director Position Number of Options David H Solomon Chief Executive Officer 50,000,000 Christopher Britten Non-Executive Chair 45,000,000 Luke Cairns Executive Director 45,000,000 Alastair Smith Non-Executive Director 35,000,000 Michael Palfreyman Non-Executive Director 25,000,000   The table at the end of this announcement, which is provided in accordance with the requirements of the UK Market Abuse Regulation, provides further details.   - Ends -   For more information please contact:   Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer   Via Thalia Investor Hub https://investors.thaliatx.com/link/exow8y SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) Tel: +44 (0)20 3470 0470 Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/ Guy McDougall  Tel: +44 (0)20 3657 0050 Northstar Communications Limited Investor relations and Communications Sarah Hollins   Cohesion Bureau Investor relations and Communications Mary-Ann Chang Tel: +44 (0)20 7183 2463         Tel: +44 (0)7483 284853     About Thalia Therapeutics plc   Thalia Therapeutics is a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies across oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat disease at its source by silencing or modifying the genes that cause or contribute to it.   Our clinical-stage programme miRisten is a microRNA therapeutic in development for Acute Myeloid Leukaemia (AML). Alongside this, our preclinical bispecific siRNA programme is being developed as a potentially long-acting treatment for atherosclerotic cardiovascular disease by addressing two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec®, offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.   For further information visit   www.thaliatx.com   Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.    1 Details of the person discharging managerial responsibilities / person closely associated a) Name 1.    David Solomon (Chief Executive) 2.    Chris Britten (Non-Executive Chair) 3.    Luke Cairns (Executive Director) 4.    Alastair Smith (Non-Executive Director) 5.    Michael Palfreyman (Non-Executive Director)   2 Reason for the notification a) Position/status See 1 a) b)   Initial notification /Amendment Initial notification     3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Thalia Therapeutics plc     b) LEI 213800OIN8T68PM7HK77   4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted   a)   Description of the financial instrument, type of instrument   Identification code Options over Ordinary Shares of 0.4p each         Identification code (ISIN) for Thalia Therapeutics plc ordinary shares: GB00BYW8QM32   b) Nature of the transaction Grant of options     c) Price(s) and volume(s) Name Exercise Price Volume(s) 1.            David Solomon 2.            Chris Britten 3.            Luke Cairns 4.            Alastair Smith 5.            Michael Palfreyman 0.6 pence 0.6 pence 0.6 pence 0.6 pence 0.6 pence   50,000,000 45,000,000 45,000,000 35,000,000 25,000,000   d) Aggregated information - Aggregated volume - Price   n/a e) Date of the transaction 20 July 2026 f) Place of the transaction Outside a trading venue    

View stock analysis, news, and events for Thalia Therapeutics Plc